This month, Myriad announced that it plans to launch a hereditary cancer panel based on next-generation sequencing by the end of the year and that it would phase out its Sanger-based BRACAnalysis test by 2015, causing some experts to speculate how Myriad's entry into next-gen seq
The American College of Medical Genetics and Genomics last week issued a clarification to recommendations it released in March about how providers of clinical exome and whole-genome sequencing tests should deal with incidental findings.
Ambry Genetics and GE Healthcare, who each released a new 26-gene sequencing service last week, have disclosed that both of their new services are based on Illumina's TruSight Tumor panel for somatic variant detection in solid tumors on the MiSeq platform.
Illumina has launched TruSight Tumor Content, an amplicon-based panel that targets 26 oncogenes and tumor suppressor genes selected associated with common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.
PHOENIX (GenomeWeb News) – Whole-exome sequencing is inching its way into the clinic, and at the American College of Medical Genetics and Genomics annual meeting held here geneticists and clinicians showed how such sequencing could be used to find diagnoses for patients whose conditions had remai
With 10,000 next-generation sequencing-based diagnostic tests performed since 2010, including more than 1,000 exome sequencing tests, Ambry Genetics plans to develop additional panels in the areas of rare disease and oncology, and expand some of its existing panels.
NEW YORK (GenomeWeb News) – Exact Sciences said in its 10-K filing with the US Securities and Exchange Commission this week that in December it entered into an amendment to a licensing agreement pursuant to which Hologic granted the company a non-exclusive worldwide license to certain Hologic pat